David A. Carmel

Biotech Executive, Henry Crown Fellow @AspenInstitute, New York Life Science Advisory Board, handcycle enthusiast, lover of the Adirondacks

[David A. Carmel @davidacarmel]

Thank you @TODAYshow and @tvkatesnow for highlighting the incredible work done by @jasoncarmel and our commitment to bring new therapies to patients.

[TODAY @TODAYshow]

Identical twins David and Dr. Jason Carmel are playing a key part in innovative medical treatment for people who are paralyzed. @TVKateSnow brings us this story.

[Foundation for the National Institutes of Health @FNIH_Org]

The BGTC knows the current number of therapies for rare diseases just isn’t good enough. We are pleased to announce our clinical trial portfolio, aiming to make gene therapies more accessible and sustainable no matter the size of the patient population. https://t.co/IBcGKy2LeO

[Foundation for the National Institutes of Health @FNIH_Org]

“What is a #RareDisease?” is the first in our series recognizing #RareDiseaseDay on Feb 28. See the full video premiere first, learn more about AMP® #BGTC, and watch a #GeneTherapy animation by signing up for our newsletter: https://t.co/nQzzX1xB09
#RDDNIH #ShowYourStripes

[Foundation for the National Institutes of Health @FNIH_Org]

FNIH co-funded a recent multinational trial showing that a low-cost, single-dose antibiotic can reduce the risk of life-threatening sepsis in women giving birth. The trial results have the potential to significantly improve maternal health worldwide: https://t.co/LcvTZxx2RP

[David A. Carmel @davidacarmel]

We envision a world in which the supply of transplantable organs and cells does not determine the length or quality of one’s life.

#WorldHealthDay #HealthierTomorrow

[eGenesis @eGenesisBio]

#WorldHealthDay is a time to raise awareness of the critical wellness issues affecting our communities. Right now, more than 20 people in the US die every day waiting for a transplant. That is why we are working to put an end to the transplant shortage for a #healthiertomorrow.

[David A. Carmel @davidacarmel]

We are delighted to welcome Eliezer Katz to the eGenesis, Inc. leadership team as our CMO. His experience as a transplant surgeon and therapeutics developer will be invaluable as we move into human clinical trials. #clinicaltrials #xenotransplantation

[eGenesis @eGenesisBio]

We’re excited to welcome Eliezer Katz, M.D., FACS, as our Chief Medical Officer who has nearly 20 years of experience as a #transplant surgeon and has become a leader in clinical development of therapeutics in transplant #immunology.

See: https://t.co/vsbHg0IAlB

[David A. Carmel @davidacarmel]

We wouldn’t be where we are today as a biotechnology company without the guidance and expertise of the @eGenesisBio doctors. We appreciate all that you do on this #NationalDoctorsDay

[eGenesis @eGenesisBio]

Today we recognize all the hard-working doctors, especially those physicians on our Board of Directors and Advisory Boards, who are helping us advance our human compatible organs and cells towards patients in need of a transplant.

#NationalDoctorsDay

[eGenesis @eGenesisBio]

Today we recognize all the hard-working doctors, especially those physicians on our Board of Directors and Advisory Boards, who are helping us advance our human compatible organs and cells towards patients in need of a transplant.

#NationalDoctorsDay

[David A. Carmel @davidacarmel]

Don't miss my colleague Mike Curtis presenting tomorrow on our work on #HuCo organs and cells at the @CareDx Xenotransplantation Innovation Day.

[eGenesis @eGenesisBio]

Tomorrow, our President of R&D, Mike Curtis, Ph.D., is participating in a Xenotransplantation Innovation Day hosted by @CareDx. He will cover the “Development of our Human Compatible (HuCo) Organs and Cells with the EGEN Platform.”

To view, register here: https://t.co/zvw6WHGTb6

[David A. Carmel @davidacarmel]

The @eGenesisBio team is excited to be working with such talented individuals at @univmiami, Miller School of Medicine on a project that has the potential to improve the lives of 1.6 million Americans currently living with type 1 diabetes.

[eGenesis @eGenesisBio]

We are excited to announce our research collaboration with the @univmiami Leonard M. Miller School of Medicine to evaluate human compatible islet cells in a clinically relevant diabetes model. This is a prerequisite to advancing to human trials.

See: https://t.co/cJ6pF6Grdz

[David A. Carmel @davidacarmel]

We have an outstanding group of women leaders at eGenesis. I am inspired by their intelligence, passion and kindness and grateful for the opportunity to work with each of them. #iwd

[eGenesis @eGenesisBio]

This #InternationalWomensDay, we celebrate and acknowledge all the incredible women of eGenesis and the achievements they have made to help further our mission. #BreaktheBias #IWD

[David A. Carmel @davidacarmel]

Shameka’s perseverance through her kidney transplant journey is one of the many reasons all of us at @eGenesisBio are working to provide more human compatible organs to patients in need and spread awareness of #NationalKidneyMonth.

[eGenesis @eGenesisBio]

This #NationalKidneyMonth, we recognize people like Shameka who are in need of a kidney transplant. Patients like her are why we are working to make safe and reliable human compatible kidneys available to everyone in need.

For Shameka’s story: https://t.co/xwCAGQM8rI

[David A. Carmel @davidacarmel]

My colleague Mike Curtis tells Science News why we prioritize kidney transplant at @eGenesisBio.

[eGenesis @eGenesisBio]

Mike Curtis, our President of R&D, explains to @ScienceNews why @eGenesisbio is focused first on human-compatible kidney transplant. 83 percent of the transplant waiting list are people who need kidneys

Read here: https://t.co/GatS4Xh7Aj

#xentotransplant

[eGenesis @eGenesisBio]

Mike Curtis, our President of R&D, explains to @ScienceNews why @eGenesisbio is focused first on human-compatible kidney transplant. 83 percent of the transplant waiting list are people who need kidneys

Read here: https://t.co/GatS4Xh7Aj

#xentotransplant

[David A. Carmel @davidacarmel]

I had the privilege of speaking with @TRIO_National about developments in xenotransplantation. Thank you, Jim Gleason, National President, and Bill Soloway, Philadelphia Chapter President, for the opportunity to hear from transplant recipients!

#engineeringhope #transplant

[eGenesis @eGenesisBio]

Our SVP of Public Affairs & Communication @davidacarmel spoke with @TRIO_National about recent developments in #xenotransplantation.
We strive to include the voice of transplant recipients in everything we do.
More on eGenesis: https://t.co/Zc8B1vK4bl
#engineeringhope #transplant

[David A. Carmel @davidacarmel]

How much of the recent news on xenotransplantation is hype? My colleague Mike Curtis breaks it down in this excellent article in @TCTMD.

[eGenesis @eGenesisBio]

Mike Curtis, our President of R&D, discusses @eGenesisbio’s view on the long-term outlook for HuCo™ organ transplants and how they could address the organ shortage with @TCTMD_Yael of @TCTMD.

Read here: https://t.co/Zb9LziasGN

[David A. Carmel @davidacarmel]

I look forward to sharing the eGenesis story to the @NewYorkBIO community!

Details here: https://t.co/NaH8VOuOCP

[eGenesis @eGenesisBio]

@davidacarmel, our SVP of Public Affairs & Communications, will be presenting at the @NewYorkBIO Emerging Biotech Company Showcase on Monday, December 6th.

Event details here: https://t.co/TDTnImCWQ1

[David A. Carmel @davidacarmel]

eGenesis has come along way since I joined the company nearly two years ago, and I am proud to share the launch of our new website to share more about our story with all of you. Please take a look at the new https://t.co/oQ1iT4apRn.

[eGenesis @eGenesisBio]

We’re pleased to announce the launch of our new website!

Find out how we’re working toward a world where no one dies waiting for an organ or cell transplant.

https://t.co/Wy9jh4lILk

[David A. Carmel @davidacarmel]

eGenesis is looking to add a new member to its immunology team in Cambridge!

[eGenesis @eGenesisBio]

Seeking an innovative Scientist with a strong background in B cell immunology to join our team!

Apply here: https://t.co/nfvZlm18v4

[David A. Carmel @davidacarmel]

The good news is that outcomes for kidney transplant have improved in the last quarter century. The bad news is that most patients in need won't receive one. At eGenesis, we are trying to end the #OrganShortage crisis.

[eGenesis @eGenesisBio]

Outcomes for kidney transplant have improved over the past 25 years. However, this treatment isn’t available for many patients because of the #OrganShortage crisis.

Read more: https://t.co/cl4A4HNvRe